tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Judah Frommer, 123 are a BUY (72.78%), 41 are a HOLD (24.26%), 5 are a SELL (2.96%).
Analyst Judah Frommer, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 58.3% that have a potential upside of 32.11% achieved within 212 days.
Judah Frommer’s has documented 324 price targets and ratings displayed on 33 stocks. The coverage is on Consumer Defensive, Consumer Cyclical, Healthcare sectors.
Most recent stock forecast was given on SRPT, Sarepta Therapeutics at 16-Jun-2025.
Analyst best performing recommendations are on ACLX (ARCELLX).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 5/15/2023. The price target of $151 was fulfilled within 1 day with a profit of $6.19 (3.94%) receiving and performance score of 39.38.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$130
$15.59 (13.63%)
$105
9 days ago
(22-Jul-2025)
18/28 (64.29%)
$15.23 (13.27%)
388
Hold
$120
$5.59 (4.89%)
$81
10 days ago
(21-Jul-2025)
5/6 (83.33%)
$7.69 (6.85%)
92
Buy
$138
$23.59 (20.62%)
$111
10 days ago
(21-Jul-2025)
19/28 (67.86%)
$25.69 (22.87%)
258
Hold
$100
$-14.41 (-12.60%)
$95
1 months 26 days ago
(05-Jun-2025)
18/37 (48.65%)
$3.33 (3.44%)
71
Hold
$85
$-29.41 (-25.71%)
$70
1 months 26 days ago
(05-Jun-2025)
14/19 (73.68%)
$-11.67 (-12.07%)
70
Which stock is Judah Frommer is most bullish on?
Which stock is Judah Frommer is most reserved on?
What Year was the first public recommendation made by Judah Frommer?
